Moderna/Merck cancer vaccine plus Keytruda delays skin cancer return
An experimental mRNA cancer vaccine developed by Moderna Inc. and Merck & Co. cut the risk of death or recurrence of the most deadly skin cancer by 44% compared with Merck‘s immunotherapy Keytruda alone, US researchers reported